An interventional study of Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope in Wilson's Disease, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 13th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 7+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 12+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–70
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+ · Healthy volunteers
Orphalan · Sites in France, Belgium, Germany and 4 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 30 across 44 interventional studies indexed under Hepatolenticular Degeneration.
Median enrollment 40 across the 11 interventional studies, 150 across the 6 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 7 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 7 studies filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatolenticular Degeneration with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430359Hospices Civils de LyonCircadian Variation of Urinary Copper Excretion in Wilson Disease Patients | 2027-02-10 |
| NCT05183165Fondation Ophtalmologique Adolphe de RothschildDescription of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease | 2027-03 |
| NCT05444127Fondation Ophtalmologique Adolphe de RothschildOral Health and Wilson's Disease: SOMAWI | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).
Procedure: Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope
The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
Contrast-enhanced cardiac MRI - Day 0
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Time frame: Day 0
Contrast-enhanced cardiac MRI - Day 0
Description of abnormalities (frequency and percentage)
Time frame: Day 0
Transthoracic echocardiography - Day 0
Percentage of patients with abnormal transthoracic echocardiography results
Time frame: Day 0
Transthoracic echocardiography - Day 0
Description of abnormalities (frequency and percentage)
Time frame: Day 0
Chest computed tomography scan without contrast - Day 0
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Time frame: Day 0
Electrocardiogram - Day 0
Percentage of patients with abnormal electrocardiogram results
Time frame: Day 0
Electrocardiogram - Day 0
Description of abnormalities (frequency and percentage)
Time frame: Day 0
Clinical examination - Day 0
Percentage of patients with abnormal clinical examination
Time frame: Day 0
Clinical examination - Day 0
Description of abnormalities (frequency and percentage)
Time frame: Day 0
Blood and urine tests - Day 0
Percentage of patients with abnormal blood and urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time frame: Day 0
Blood and urine tests - Day 0
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time frame: Day 0
Lying and standing blood pressure tests - Day 0
Percentage of patients with abnormal blood pressure tests results
Time frame: Day 0
Lying and standing blood pressure tests - Day 0
Description of abnormalities (frequency and percentage)
Time frame: Day 0
Implantable loop recorder or ECG holter recorder- Day 21
Percentage of patients with abnormal implantable loop record (or ECG holter record) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Time frame: Day 21
Implantable loop recorder or ECG holter recorder- Day 21
Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Time frame: Day 21
Transthoracic echocardiography - Year 3
Percentage of patients with abnormal transthoracic echocardiography results
Time frame: Year 3
Transthoracic echocardiography - Year 3
Description of abnormalities (frequency and percentage)
Time frame: Year 3
Contrast-enhanced cardiac MRI - Year 3
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Time frame: Year 3
Contrast-enhanced cardiac MRI - Year 3
Description of abnormalities (frequency and percentage)
Time frame: Year 3
Chest computed tomography scan without contrast - Year 3
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Time frame: Year 3
Electrocardiogram - Year 3
Percentage of patients with abnormal electrocardiogram results
Time frame: Year 3
Electrocardiogram - Year 3
Description of abnormalities (frequency and percentage)
Time frame: Year 3
Clinical examination - Year 3
Percentage of patients with abnormal clinical examination
Time frame: Year 3
Clinical examination - Year 3
Description of abnormalities (frequency and percentage)
Time frame: Year 3
Blood and urine tests - Year 3
Percentage of patients with abnormal blood or urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time frame: Year 3
Blood and urine tests - Year 3
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time frame: Year 3
Lying and standing blood pressure tests - Year 3
Percentage of patients with abnormal blood pressure tests results
Time frame: Year 3
Lying and standing blood pressure tests - Year 3
Description of abnormalities (frequency and percentage)
Time frame: Year 3
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Mar 2029, 72 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2026 → Mar 2029 and completion Mar 2026 → Mar 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatolenticular Degeneration →
Fondation Ophtalmologique Adolphe de Rothschild →